ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 671,34
1,34%
Dow Jones
39 134,76
0,77%
DAX
18 254,18
1,03%
Brent Oil
85,045
0,41%
Bitcoin
64 974,67
0,01%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. IGC Pharma Inc (IGC)

  7. IGC Pharma Inc (IGC) Actualités

IGC IGC Pharma Inc

0,4227
0,0217 (5,41%)
Après les heures de négociation
Dernière mise à jour : 22:15:11
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
IGC Pharma Inc IGC AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,0217 5,41% 0,4227 22:15:11
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,402 0,4012 0,4221 0,4026 0,401
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/6/202415:00BWIGC Pharma to Participate in Fireside Chat with Ascendiant..
10/6/202415:00BWIGC Pharma Publishes Study in European Society of Medicine..
28/5/202415:00BWIGC Pharma Announces Patient Enrollment at Neurostudies in..
22/5/202403:20EDGAR2Form SC 13D - General statement of acquisition of beneficial..
21/5/202420:00BWIGC Pharma to Attend BIO International Convention 2024
14/5/202403:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202403:53EDGAR2Form 3 - Initial statement of beneficial ownership of..
16/4/202413:00BWIGC-AD1’s Interim Phase 2 Data Show a Reduction in..
09/4/202415:00BWIGC Pharma Adds Advisor in Artificial Intelligence
26/3/202420:00BWIGC Pharma Announces $3 Million Unregistered Private..
20/3/202416:00BWIGC Pharma Announces Positive Interim Results for IGC-AD1 in..
20/3/202412:00BWIGC PHARMA Announces its Participation at the Benzinga..
12/3/202420:00BWIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins..
28/2/202419:00BWPromising Results: TGR-63 Enhances Memory in Alzheimer's..
23/2/202418:01BWIGC Pharma Announces Equity Analyst Coverage by Ascendiant..
17/2/202401:05BWIGC Pharma Reports Third Quarter Fiscal 2024 Results
14/2/202422:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/2/202415:20BWIGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's..
31/1/202422:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
23/1/202415:20BWIGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63..
17/1/202415:20BWIGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing..
29/12/202322:54EDGAR2Form S-3 - Registration statement under Securities Act of..
19/12/202315:20BWPatent Granted to IGC Pharma for Groundbreaking Drug..
13/12/202315:30BWIGC Pharma Announces Participation in Biotech Showcase and..
06/12/202314:30BWIGC Pharma Announces Collaboration to Integrate AI into..
21/11/202314:30BWIGC Pharma Announces Master Agreement with Leading South..
13/11/202314:00BWIGC Pharma Reports Second Quarter Fiscal 2024 Results
09/11/202323:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
27/10/202323:21EDGAR2Form 8-K - Current report
27/10/202322:38EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/10/202321:30BWIGC Pharma Granted European Patent for Groundbreaking..
29/9/202323:23EDGAR2Form S-3 - Registration statement under Securities Act of..
21/8/202320:30BWIGC Announces Results of its 2023 Annual Stockholders..
21/8/202318:44EDGAR2Form 8-K - Current report
14/8/202314:30BWIGC Pharma Reports First Quarter Results; Company Continues..
10/8/202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/8/202314:30BWIGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the..
26/7/202323:26EDGAR2Form DEF 14A - Other definitive proxy statements
18/7/202311:22BWIGC Pharma, Inc. Presenting 6 Posters on the Positive Impact..
12/7/202314:44BWIGC Reports Financial Results for Fiscal Year Ended March..
07/7/202322:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07/7/202317:41EDGAR2Form 8-K - Current report
07/7/202315:15BWIGC Pharma Secures $12 Million Line of Credit from O-Bank..
06/7/202313:46BWIGC Pharma Announces a $3 Million Private Placement of its..
30/6/202322:03EDGAR2Form NT 10-K - Notification of inability to timely file Form..
29/6/202303:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/6/202319:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

AMEX
IGC
IGC Pharma
BIT
P1Z6B7
NLBNPIT1Z6B7 20991231 19...
EU
BE0002678598
Bruca Bruca 1.053% until...
LSE
IWDP
Ishr Dm Prop
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés